epocrates

Drug Updates: Week of February 9, 2026

February 16, 2026

Here's a quick roundup of last week’s new drug monographs and updates.

New Brand Monograph

Yuvezzi (carbachol/brimonidine ophthalmic)

• Indications: presbyopia
• Formulation: ophthalmic solution
• Read more: FDA greenlights Yuvezzi drops for presbyopia

New and Expanded Dosage Regimens

iDose TR (travoprost intracameral)

• New: elevated intraocular pressure (may re‑administer implant 1/yr)
• Affected indications: elevated intraocular pressure (max: 1 implant/eye)
• Read more: FDA OKs label change allowing for re-administration of iDose TR

Verquvo (vericiguat)

• New: symptomatic heart failure with reduced ejection fraction (start 5 mg PO daily; double dose every 2 weeks as tolerated)
• Affected indications: symptomatic heart failure with reduced ejection fraction (start 2.5 mg PO daily; double dose every 2 weeks as tolerated)

Investigational New Drug (IND)

Anaphylm (dibutepinephrine)

• Proposed indications: anaphylaxis in adult and pediatric patients
• Status: FDA approval denied, February 2026